ArticleFrontiers in health services2026
Lifecycle regulation of private equity in healthcare: a transatlantic governance framework.
Article in Frontiers in health services, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Private equity (PE) investment in healthcare has expanded rapidly across the United States (US) and the European Union (EU), reshaping ownership structures in primary care, specialty services, and ancillary providers. This trend has generated both optimism about capital infusion and operational efficiencies and concern about financialization, short investment horizons, and risks to care quality and equity. In this Perspective, we argue that PE participation in healthcare constitutes a systemic governance risk requiring lifecycle regulation -from acquisition through ownership to exit- rather than regulation focused narrowly on ownership status. Building on current empirical evidence and policy debates, we advance a transatlantic governance framework with five core domains: transparency, financial safeguards, clinical autonomy, quality assurance, and workforce protection. We propose context-sensitive implementation tailored to US and EU institutional realities and discuss trade-offs between regulation and investment incentives, including gaps in ownership transitions and exit phases. Finally, we outline priority research and policy experimentation to support proportionate oversight balancing innovation with patient interests and public accountability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.